Classical non-homologous end joining 1 (cNHEJ) and homologous recombination 2 compete for the repair of double-stranded DNA breaks during the cell cycle. Homologous recombination is inhibited during the G1 phase of the cell cycle, but both pathways are active in the S and G2 phases. However, it is unclear why cNHEJ does not always outcompete homologous recombination during the S and G2 phases. Here we show that CYREN (cell cycle regulator of NHEJ) is a cell-cycle-specific inhibitor of cNHEJ. Suppression of CYREN allows cNHEJ to occur at telomeres and intrachromosomal breaks during the S and G2 phases, and cells lacking CYREN accumulate chromosomal aberrations upon damage induction, specifically outside the G1 phase. CYREN acts by binding to the Ku70/80 heterodimer and preferentially inhibits cNHEJ at breaks with overhangs by protecting them. We therefore propose that CYREN is a direct cell-cycle-dependent inhibitor of cNHEJ that promotes error-free repair by homologous recombination during cell cycle phases when sister chromatids are present.
12,000 cells analysed. e, Percentage of cells with fusions ± upper and lower value of 95% confidence intervals, Wilson-Brown test. * * * * P < 0.0001, * * * P < 0.001, * * P < 0.01; NS, not significant. Fisher's exact test, two-sided. n, number of metaphases analysed. KO, knockout; WT, wild type. f, Top, experimental outline. Bottom, mean percentage of fused ends per metaphase. Error bars, s.e.m. * * * P < 0.001, * * P < 0.01,
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during and after replication. Similarly, fusions of telomeres deprotected by TRF2 suppression, which occur through cNHEJ exclusively, are restricted to G1 4,5 . End resection, which promotes HR, is inhibited by the DNA repair-associated proteins RIF1 and 53BP1 during G1, thereby restricting HR activity to S and G2 [6] [7] [8] . During S and G2, when both pathways are active 9 , end resection by the endonuclease CtIP is activated, which can inhibit cNHEJ 10 . However, it is unclear how cNHEJ is restricted during S and G2 to allow resection and commencement of HR for error-free repair of lesions. CYREN was originally identified as a potential modulator of retroviral infection 11 . Later, the alternatively spliced isoform CYREN-2 was found to exist as a short open reading frame-encoded polypeptide and to interact with the Ku70/80 heterodimer 12 . We therefore tested the role of CYREN in cNHEJ and found it to be a cell cycle-dependent regulator of cNHEJ.
TRF2 (telomeric repeat-binding factor 2) protects telomeres by stabilizing the t-loop and inhibiting the ATM kinase and the E3 ubiquitin-protein ligase RNF168 [13] [14] [15] . Depletion of TRF2 leads to ATM activation 16 and subsequent activation of cNHEJ, leading to chromosome end-to-end fusions 17 , while HR and alternative NHEJ (altNHEJ) remain inhibited by shelterin and Ku70/80 [18] [19] [20] . Chromosome fusions before replication occur between the single chromatids of two chromosomes, leading to chromosome-type fusions after replication, where both sister chromatids are fused. When fusions occur after replication, only one sister chromatid is engaged in the fusion, leading to chromatid-type fusions (Fig. 1a) . Chromosomes fused as a result of loss of TRF2 display as chromosome-type fusions during metaphase, demonstrating that the fusion process is restricted to the G1 phase of the cell cycle and suppressed during S and G2 4, 5, 21, 22 . The emergence of chromatid-type fusions signifies derepression of cNHEJ in S and G2 (Fig. 1a) , representing a powerful system in which to investigate DSB repair pathway choice. To study the role of CYREN in cNHEJ, we generated human fibrosarcoma HT1080 6TG cells with three stably integrated inducible short hairpin RNAs (shRNAs) targeting C7orf49, which encodes CYREN (shCYREN A, B and C), which were induced after TRF2 depletion followed by metaphase analysis (Extended Data Figs 1a-c, 10). Depletion of TRF2 alone led to chromosome-type G1 fusions, while chromatid-type fusions were rare (Fig. 1b, c , Extended Data Fig. 1d, e) . Overall, chromosome-type telomere fusion frequency was unaltered by CYREN depletion (Fig. 1c, Extended Data Fig. 1d, e, g ), indicating that CYREN is not part of the cNHEJ machinery. Instead, depletion of CYREN and TRF2 led to a fivefold increase in chromatidtype fusions (Fig. 1b, c, Extended Data Fig. 1d, e, g ), suggesting that CYREN could suppress cNHEJ in S and G2 at deprotected telomeres. Sister telomere associations were not increased (Extended Data  Fig. 1f, g ) and cell cycle dynamics were not perturbed by shRNA treatment (Fig. 1d) . Untransformed IMR90-E6E7 fibroblasts reacted similarly (Extended Data Fig. 2a-d) . CYREN depletion did not lead to chromatid-type fusions at intact telomeres, indicating that CYREN itself does not play a role in end protection (Fig. 1b, c , Extended Data Fig. 1d, e) .
Chromosome-oriented fluorescence in situ hybridization (FISH) on cells depleted of both CYREN and TRF2 found no bias in the type of chromatid involved in chromatid-type fusions, ruling out the possibility that the observed fusions are a result of unprocessed leading strand overhangs 23,24 (Extended Data Fig. 3a, b) . To determine whether the fusions were the result of cNHEJ or altNHEJ activation, we depleted ATM, ligase 4, the catalytic subunit of DNA-dependent protein kinase (DNA-PKcs) and ligase 3 in TRF2-suppressed cells that either expressed wild-type CYREN (CYREN WT ) or had CYREN knocked out (CYREN KO ) (Extended Data Fig. 3c, d ). Only depletion of ATM, ligase 4 or DNA-PKcs suppressed both chromosome-and chromatid-type fusions, indicating that CYREN regulates cNHEJ, not altNHEJ (Fig. 1e) . Inhibitors of ATM, DNA-PKcs or poly ADP ribose polymerase (PARP)
25-27 had comparable effects, whereas inhibition of the HR-associated protein RAD51
28 had no effect, ruling out the possibility that CYREN controls HR (Extended Data Fig. 3e, f) . Inhibition of ATM and DNA-PKcs throughout the cell cycle (48 h) suppressed both chromosome-and chromatid-type fusions as expected (Fig. 1f) . When inhibition occurred just during the S and G2 phases (9 h), only the chromatid-type fusions were suppressed, indicating that they were indeed generated after G1. Inhibition during G2 (4 h) partially suppressed chromatid-type fusion formation, indicating that these fusions are generated in both S and G2 (Fig. 1f) . These data confirm that CYREN inhibits cNHEJ in the S and G2 phases at deprotected telomeres.
To demonstrate that CYREN is a genome-wide regulator of DSB repair pathway choice, we first tested the effects of CYREN deletion on the repair of irradiation-induced intrachromosomal breaks. While three synchronized CYREN WT and CYREN KO clones (Extended Data Fig. 10 ) accumulated rearrangements or bridges after irradiation during G1, cells lacking CYREN amassed substantially more abnormalities when irradiated during and after replication than did wild-type cells (Fig. 2a, b, Extended Data Fig. 4a, b Letter reSeArCH at intrachromosomal breaks in S and G2. We then designed an in vivo fluorescence-based reporter system that allows the quantitative comparison of cNHEJ and altNHEJ with homologous recombination in the same cells through the repair of two inverted ISce1 cuts. Repair through NHEJ or HR leads to expression of GFP or mCherry, respectively, and transfection efficiency was controlled using BFP expression from the repair donor cassette (Fig. 2c, Extended Data Figs 4c, d, 10 ). We confirmed that all isolated reporter clones followed the same cell cycle kinetics (Extended Data Fig. 4e ) and analysed the outcome of repair by flow cytometry. The CYREN KO clones used NHEJ significantly more frequently than the CYREN WT clones (P = 0.009), while HR was significantly reduced in the same cells (P = 0.001) (Fig. 2d) , confirming CYREN as the pathway choice regulator. CYREN depletion did not lead to the formation of radial chromosomes, to an increase in radials in cells lacking Brca1, or to a decrease in survival (Extended Data Fig.  5a -c), suggesting that CYREN is not involved in replication-induced DSB repair, where HR is dominant.
As a result of alternative splicing of C7orf49, three isoforms of CYREN are generated (Fig. 3a) , of which isoforms 1 and 2 were found to bind to Ku70/80 12 . We expressed the Flag-tagged isoforms, depleted TRF2 and suppressed endogenous CYREN by targeting the 3′ UTR of C7orf49 with a short interfering RNA (siRNA) (Extended Data Fig. 6a, b) . Suppression of CYREN in this way increased chromatid-type fusions in control cells or cells expressing CYREN-3, but expression of CYREN-1 or CYREN-2 rescued the phenotype (Fig. 3b) , indicating that these isoforms inhibit cNHEJ.
To verify the endogenous expression levels of the isoforms, we inserted a 3× Flag tag at the N terminus of CYREN-1 and -2 and the C terminus of CYREN-1 and -3 (Extended Data Figs 6c-h, 10). CYREN-1 was six to seven times more abundant than CYREN-2 (Extended Data Fig. 6e ), CYREN-3 expression was not detectable (Extended Data Fig. 6h ) and the siRNA targeting C7orf49 indeed targeted endogenous CYREN (Extended Data Fig. 6i ). We therefore focused on CYREN-1.
To identify the CYREN-1-Ku interaction domain, we incubated a CYREN-1 peptide array with recombinant Ku70/80 (Extended Data  Fig. 7a ). Ku70/80 bound to several peptides on the N terminus of CYREN-1, a region that is lacking in CYREN-3. Alanine mutagenesis, followed by co-immunoprecipitation of Ku70/80 with mutated CYREN-1, identified R11, P14 and W16 as the precise interaction domain (Fig. 3c, Extended Data Fig. 7b ). These highly conserved residues (Extended Data Fig. 7c) are part of the Ku-binding motif (KBM), which has previously been described in aprataxin polynucleotide kinase/phosphatase-like factor (APLF), CYREN and the Werner syndrome helicase (WRN) and has been shown to interact with a hydrophobic pocket in the vWA domain of Ku80
29
. We incubated a synthetic UV-crosslinkable BPA-BIO-CYREN (benzoyl phenylalaninebiotin-CYREN) peptide with cell lysate, followed by UV crosslinking Letter reSeArCH and biotin pulldown, and confirmed that the KBM of CYREN interacted directly with Ku80 (Extended Data Fig. 7d ). Co-depletion of CYREN and TRF2 again led to chromatid-type fusions, which were suppressed by exogenous expression of wildtype CYREN-1 or CYREN-1 R11A (Fig. 3d , Extended Data Fig. 7e ). By contrast, expression of the CYREN-1 P14A and CYREN-1 W16A mutants, as well as the triple mutant CYREN-1 RPW-AAA , failed to rescue the chromatid-type fusions (Fig. 3d ), indicating that CYREN-mediated inhibition of cNHEJ depends critically on the interaction of CYREN with Ku.
Because CYREN activity is restricted to S and G2, we examined the cell cycle regulation of CYREN. The levels of CYREN-1 and CYREN-2 mRNA and of endogenous C-terminally tagged CYREN-1 or endogenous N-terminally tagged CYREN-1 and CYREN-2 proteins were not cell cycle regulated (Fig. 3e , f, Extended Data Fig. 7f ). By contrast, the interaction of CYREN with the Ku heterodimer was restricted to S and G2 of the cell cycle (Fig. 3g, h ), explaining the cell cycle dependence of CYREN-based inhibition of c-NHEJ.
To understand whether CYREN has a preference for break sites with pre-existing overhangs, we generated breaks with either blunt ends or 5′ or 3′ overhangs of different lengths at an mClover-lamin A reporter (Fig. 4a, Extended Data Fig. 10 ). We found that although CYREN depletion did not affect the repair of blunt ends, HR was reduced at breaks with overhangs ( Fig. 4b, Extended Data Fig. 8a ). The reduction reached up to 40% at breaks with long 3′ overhangs, suggesting that CYREN preferentially regulates cNHEJ at breaks with overhangs, consistent with the strong inhibition of cNHEJ observed at telomeres. To analyse a potential role for CYREN in overhang processing during cNHEJ, we used the same reporter system without providing a HR donor. Deep sequencing and analysis of the deletions at the repair junctions revealed no increase in deletion frequencies at blunt ends, but the lack of CYREN led to increased deletions of the 5′ and 3′ overhangs, indicating that CYREN prevents the processing of overhangs (Fig. 4c , Extended Data Fig. 8b ). This phenotype was rescued by CYREN WT expression, but not by the CYREN mutant that fails to interact with Ku70/80 (Extended Data Fig. 8c, d ). The data suggest that CYREN protects single-stranded overhangs at break sites, thereby creating a local environment that favours HR, while preventing cNHEJdependent repair. CYREN had previously been described as a stimulator of end joining in vitro 12 . However, when we compared the in vitro NHEJ activities of CYREN KO and CYREN WT clones, we did not observe any differences (Extended Data Fig. 9a ). Similarly, purified wild-type CYREN or CYREN incapable of binding to Ku did not stimulate end joining activity (Extended Data Fig. 9b ), leading us to the conclusion that the small differences reported previously were likely to be the consequences of oversaturating the reaction with recombinant protein.
CYREN represents a novel class of pathway choice regulators that is not a functional part of the cNHEJ or HR machineries per se. It is possible that the CYREN-Ku interaction diminishes binding of Ku to break sites with overhangs. Similarly, CYREN could compete for Ku binding with other KBM-containing factors in vivo, thereby obstructing initiation of the NHEJ process and giving the resection machinery an advantage, consistent with the observation that HR is favoured when rapid end joining by NHEJ is inhibited 30 . While inhibition of HR at replication-induced breaks eventually leads to repair by cNHEJ even in S and G2, cNHEJ at telomeres remains inhibited, possibly because the overhangs of two deprotected telomeres are not cohesive and fusion depends on overhang processing, which does not apply to the cohesive overhangs induced by nickase. CYREN could therefore suppress the fusion of distal breaks bearing overhangs and prevent translocations in S and G2. Finally, understanding CYREN will permit an in-depth analysis of the cell cycle-regulated Ku-CYREN interaction and the potential effects on toxicity of error-prone repair, whether unleashing cNHEJ in cell cycle phases other than G1 will predispose organisms to cancer and whether deregulation of cNHEJ in S and G2 sensitizes cancer cells to genotoxic drugs.
Online Content Methods, along with any additional Extended Data display items and Source Data, are available in the online version of the paper; references unique to these sections appear only in the online paper. Supplementary Information is available in the online version of the paper. 31 were grown in Glutamax-DMEM (Gibco) supplemented with 0.1 mM nonessential amino acids and 15% fetal bovine serum. All cells were grown at 7.5% CO 2 and 3% O 2 . All cell lines were purchased from ATCC or have been commercially authenticated and tested free of mycoplasma. Lentivirus was produced by the Salk Gene Transfer, Targeting and Therapeutics Core facility or in the laboratory. For virus production, 293FT cells (Thermo Fisher) were transfected with 7 μ g plasmid using Lenti-X Packaging Single-shot system (Clontech). Viral supernatant was collected 48 h after transfection and used for cell infection at a multiplicity of infection (MOI) of 2 in the presence of LentiBlast (Oz biosciences). Forty-eight hours after infection, cells were washed and selected with 1 μ g ml −1 puromycin for two days, 800 μ g ml −1 G418 ( neomycin R ) for 10 days or 75 μ g ml −1 Hygromycin B for 10 days. pRSITUR-infected cells were sorted for RFP fluorescence. siRNAs, sgRNAs, shRNAs and primers used. shRNAs plasmids and target sequences: shTRF2 pLKO.1 (Open Biosystems) ACAGAAGCAGTGGTCGAATC; shLuci pRSITUR (Cellecta) CGCTGAGTACTTCGAAATGTC; shCYREN-A pRSITUR (Cellecta) CTCTGGGAATCCTGATTGAGA; shCYREN-B pRSITUR (Cellecta) GAAGAGGATGTGCTGAAATAC; shCYREN-C pRSITUR (Cellecta) GGATGTGCTGAAATACGTCGC sgRNAs target sequences: CYREN KO and N-ter tagging: AAGGACCCTCG TTTTAGTCT. CYREN C-ter tagging: GGCCGCCCGCCTGTGGGAAT (Fig. 2d ) or 3 h, collected by trypsinization and centrifuged. Hypotonic treatment for cell swelling was performed for 7 min at 37 °C in 75 mM KCl, followed by fixation in methanol:acetic acid 3:1 (v/v). After three washes in fixative solution, cells were dropped on superfrost microscope slides and dried overnight. Slides were then rehydrated for 10 min in PBS, fixed for 2 min in 3.7% (v/v) formaldehyde in PBS and dehydrated in ethanol bath series (70%; 90%; 100%, 3 min each) and air dried. Slides were layered with 40 μ l of 0.3 ng μ l −1 Alexa488-OO-(CCCTAA) 3 PNA probe (PNA Bio Inc.) diluted in 70% (v/v) deionized formamide; 0.25% (v/v) blocking reagent (NEN); 10 mM Tris pH 7.5; 4.1 mM Na 2 HPO 4 ; 450 μ M citric acid; 1.25 mM MgCl 2 , denatured for 4 min at 76 °C and incubated for 2 h at room temperature. Slides were then washed twice for 15 min in 70% (v/v) formamide; 10 mM TrisHCl pH 7.5 and three times for 5 min in 50 mM TrisHCl pH 7.5; 150 mM NaCl; 0.08% Tween-20. Slides were stained with 50 ng ml −1 DAPI, dehydrated in an ethanol bath series, air-dried and mounted in Prolong-Gold (Thermo Fisher). CO-FISH was performed as described 36 .
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Immunoblotting. Immunoblotting was performed as described 37 and developed using a Syngene G-Box imager. Antibodies: TRF2 (Karlseder laboratory), rabbit Flag (Sigma-Aldrich, F7425), Flag (M2, Sigma-Aldrich, F1804), Tubulin (SigmaAldrich, T6557), BrdU A488 (3D4, BD Biosciences, 555627), Ku70 (V540, Cell Signalling, 4104), Ku70 (Abcam, ab3114), Ku86 (Cell Signalling, 2753), ATM (Epitomics, 1549-1), ligase 4 (EPR16531, Abcam, ab193353), DNA-PKcs (Abcam, ab70250), ligase 3 (BD Biosciences, 611876), anti-rabbit HRP (GE Healthcare, NXA931), anti-mouse HRP (GE Healthcare, NXA934V). Peptide binding assay. Peptide binding arrays were generated as previously described 38 . Membranes were activated by soaking for 2 min in methanol, washed for 5 min in TBST (Tris Borate SDS Tween), blocked for 5 min in TBST + 5% milk (TBST-M), and incubated for 24 h at 4 °C with 6 μ g ml −1 purified Ku70/80 in TBST-M, followed by incubation overnight in anti-Ku70 primary antibody diluted 1:1,000 (v/v) in TBST-M. Membranes were then washed three times for 5 min in TBST, incubated for 1 h with secondary antibody, washed three times for 15 min in TBST, revealed with ECL substrate and imaged with a Syngene G-Box imager. Co-immunoprecipitation. For the alanine scan, CYREN-1-Flag was cloned in a pcDNA3.1 construct and residues 9-46 were each mutated to an alanine using Q5 Site-Directed Mutagenesis Kit (NEB). HEK293T cells were transfected with 10 μ l empty vector, Flag-tagged CYREN1 WT or mutants using Lipofectamine 2000. Twenty-four hours after transfection, cells were harvested and lysed with Pierce IP lysis buffer (Thermo Fisher) supplemented with protease inhibitors (Roche). Protein lysates were immunoprecipitated with anti-Flag agarose beads (clone M2, Sigma Aldrich) for 1 h at 4 °C, washed 3 times with TBS-T and eluted with 125 μ g ml −1 3× Flag peptide (Sigma Aldrich) in TBS-T for 1 h at 4 °C. 2.5% of the cell total lysate and 25% of the immunoprecipitate were used for western blot analysis.
For endogenous CYREN immunoprecipitations, cells were synchronized by double thymidine block and lysed in Pierce Lysis buffer for 30 min after 2 Gy irradiation in S, G2 or G1 phase (4, 9 and 12.5 h after thymidine release, respectively). Protein lysate (500μ g ) was incubated overnight with 2 μ g rabbit anti-Flag or control IgG antibody followed by 1 h incubation with 50 μ l Dynabeads Protein G. Beads were washed five times in PBST and boiled in Laemli buffer. 2.5% of the cell total lysate and 25% of the immunoprecipitate were used for western blot analysis. Photo-crosslink pulldown. Purified CYREN 2-24 free peptide and crosslinkable CYREN 2-24 -(p-benzoyl-l-phenylalanine (BPA at residue 16)-biotin peptides were purchased from RS synthesis. Two milligrams of HEK293T cell lysate was incubated for 1 h at 4 °C with 100 μ M CYREN 2-24 free peptide (or equivalent volume of DMSO). 25-50 μ M CYREN 2-24 -BPA(16)-biotin was added and incubation was pursued for 2 h, followed by UV crosslinking (Stratalinker 1800, 365 nm) for 1 h while maintaining samples on ice. Crosslinked samples were immunoprecipitated for 1 h at 4 °C with 100 μ l streptavidin agarose beads (Thermo FISHER) and washed three times with TBS-T supplemented with 1% SDS at room temperature for 15 min each. The samples were eluted with 2× SDS loading dye and boiled for 15 min at 95 °C. SDS-PAGE and western blot analysis were performed. In vitro end-joining assay. Cells were washed three times in ice-cold PBS, resuspended in two volumes of hypotonic lysis buffer (10 mM Tris-HCl, pH 8.0, 1 mM Letter reSeArCH EDTA, 1 mM DTT plus protease inhibitors), and left for 20 min on ice. Swollen cells were lysed by homogenization and left for 20 min on ice, and 0.5 volume of high salt buffer (50 mM Tris-HCl, pH 7.5, 1 M KCl, 2 mM EDTA, 1 mM DTT) was added. Extract was centrifuged for 1 h at 20,000 rpm in a Beckman 70.1 Ti fixed angle rotor at 4 °C, using polycarbonate thick wall tubes. Supernatant was dialysed for 2-3 h against E buffer (20 mM Tris-HCl, pH 8.0, 0.1 M KOAc, 20% (v/v) glycerol, 0.5 mM EDTA, 1 mM DTT) in a cassette with a membrane cutoff of 10,000 Da. Samples were snap frozen in liquid N 2 and stored at − 80 °C. End-joining reactions (20 μ l) were carried out in 20 mM Tris-HCl (pH 7.5), 01 mM Mg(OAc) 2 , 60 mM KOAc, 2 mM ATP, 0.5 mM DTT, and 80 μ g ml −1 BSA with 40 ng cell extracts and 20 ng 32 P-labelled DNA. Incubation was for 90 min at 37 °C. 32 P-labelled DNA products were deproteinized and analysed by electrophoresis through 0.6% agarose gels followed by autoradiography. Quantification of joining efficiency was carried out using ImageJ. Linear DNA containing 3′ -overhangs was generated by cutting the plasmid pBLueScript with the endonuclease HindIII; 5′ -overhangs were generated by cutting with KpnI and blunt ends were generating using EcoRV. DSB repair reporter (DRR). The integrated DRR consists of a promoter and resistance cassette fused to a T2A peptide and two inverted ISce1 sites, followed by GFP. Intact or partially cut DRRs lack GFP expression owing to the presence of a STOP codon. Cells are transfected with ISce1 and an exogenous donor for HR. Repair by NHEJ or HR leads to GFP or mCherry expression, respectively. Protein alignment. We used PRALINE protein alignment online software: http:// www.ibi.vu.nl/programs/pralinewww/. Flow cytometry. For DNA repair reporter analysis, one million cells containing integrated reporter were nucleofected with 4 μ g pDonor HR plasmid and 2.5 μ g pCBASce plasmid. Forty-eight hours after transfection, cells were trypsinized and resuspended in 25 mM HEPES pH 7, 1% (v/v) FBS, 2 mM EDTA, 1× PBS and directly subjected to flow cytometry analysis. For the Cas9-LMNA reporter, 0.4 million cells were seeded in a 6-well plate and transfected 24 h later using Lipofectamine 3000 with 4 μ g mClover-LMNA HR donor plasmid and 2.5 μ g of a plasmid expressing Cas9 D10A and a pair of gRNAs. Cells were analysed by flow cytometry 72 h after transfection. For cell cycle analysis, cultured cells were treated for 10 min with 30 μ M BrdU, fixed in PBS/ethanol 1/3 (v/v) and labelled with Alexa488 anti-BrdU and propidium iodide. Flow cytometry was performed using MACSquant Analyzer 10 (Miltenyi) and analysed with FlowJo10. Deep sequencing. CYREN WT and CYREN KO clones were transfected as for flow cytometry analysis, except no HR donor was transfected. Four days after transfection, DNA was extracted using Quick-DNA Miniprep Plus kit (Zymo Research) and a 300-nt region around the break sites was amplified by PCR using KOD hot start polymerase (Millipore). Transfection efficiency was controlled by flow cytometry with the BFP tag on the Cas9 gRNA plasmid. PCR products were sequenced by MiSeq by Retrogen. The paired end fastq files were first merged into single continuous reads using FLASH (PMID: 21903629). Reads were then aligned to the amplified template reference sequence of the amplified template using global Smith-Waterman sequence alignment with the EMBOSS Needle program using default parameters (PMID: 10827456). Only sequences with an alignment score of at least 800 were considered. Deletions were compiled from the alignments of correctly aligning sequences. Statistical analysis. Each figure legend indicates sample size and number of independent experiments. To detect trends among multiple datasets in Figs 1c-f , 3b-h, 4b and Extended Data Fig. 2d , one-way ANOVA was used. The percentages of cells with fusions in Figs 1e, 3d and Extended Data Figs 1e and 3f were analysed by Fisher's exact test. Two tailed unpaired t-test was used in Fig. 2a, b, d and Extended Data Fig. 8c to compare two datasets where Gaussian distribution is assumed. All statistical analyses were performed using GraphPad Prism 7 software. Data availability. All data and reagents are available from the corresponding author upon reasonable request. All gel source data are available in Supplementary Fig. 1 . 
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